Ki Hong Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ki Hong Choi has a total of 530 co-authors. Here are the top co-authors by number of shared publications:
- Jeong Hoon Yang
Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
42 shared publications - Young Bin Song
Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
41 shared publications - Hyeon-Cheol Gwon
Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
39 shared publications - Joo-Yong Hahn
Sungkyunkwan University School of Medicine
37 shared publications - Joo Myung Lee
Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
35 shared publications - Seung-Hyuk Choi
Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
33 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Differential Prognostic Impact of Potent P2Y 12 Inhibitors in Patients With Acute Myocardial Infarction by Bleeding Risk
Joh HS, et al. Korean Circ J. 2027 ;57:e23. https://doi.org/10.4070/kcj.2026.0033
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Open AccessDifferential Prognostic Impact of Potent P2Y 12 Inhibitors in Patients With Acute Myocardial Infarction by Bleeding Risk
Joh HS, et al. Korean Circ J. 2027 ;57:e23. https://doi.org/10.4070/kcj.2026.0033
- Open Access
- 3 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (21) , e052821
Physical Activity and Cardiovascular Risk in Type 2 Diabetes With Normal Body Mass Index and Abdominal Obesity: A Nationwide Cohort Study
Background: The prognostic implications of abdominal obesity and moderate‐to‐vigorous physical activity (MVPA) in patients with type 2 diabetes who have a normal body mass index remain unclear. Methods: This nationwide retrospective cohort study included 323 029 adults with newly diagnosed type 2 diabetes and a normal body mass index (2 ) between January 1, 2010, and December 31, 2023, from the Korean National Health Insurance Service database. Abdominal obesity was defined using sex‐specific waist circumference thresholds (≥90 cm for men, ≥80 cm for women). MVPA was assessed through standardized self‐reported questionnaires administered during routine health screenings. The primary outcome was major adverse cardiovascular and cerebrovascular events, defined as a composite of all‐cause death, myocardial infarction, ischemic stroke, or hospitalization for heart failure. Results: Among the study population, 34 033 (10.5%) had abdominal obesity. During a median follow‐up of 6.0 years (interquartile range, 2.6–9.0 years), abdominal obesity was associated with a higher risk of major adverse cardiovascular and cerebrovascular events (adjusted hazard ratio [HR], 1.13 [95% CI, 1.09–1.17]). Among patients with abdominal obesity, regular MVPA after diagnosis (27.1%) was associated with a significantly lower risk of major adverse cardiovascular and cerebrovascular events (adjusted HR 0.74 [95% CI, 0.68–0.80]), all‐cause mortality (adjusted HR 0.72 [95% CI, 0.65–0.80]), ischemic stroke (adjusted HR 0.77 [95% CI, 0.66–0.89]), and hospitalization for heart failure (adjusted HR 0.75 [95% CI, 0.60–0.93]). The cardiovascular protective effects of MVPA were consistent regardless of statin or antidiabetic medication use. Conclusions: In patients with type 2 diabetes and a normal body mass index, abdominal obesity was independently associated with a higher risk of major adverse cardiovascular and cerebrovascular events. Regular engagement in MVPA showed consistent cardiovascular benefits in this population, irrespective of pharmacotherapy. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT07071545.
- 3 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (21) , e052821
Open AccessPhysical Activity and Cardiovascular Risk in Type 2 Diabetes With Normal Body Mass Index and Abdominal Obesity: A Nationwide Cohort Study
Background: The prognostic implications of abdominal obesity and moderate‐to‐vigorous physical activity (MVPA) in patients with type 2 diabetes who have a normal body mass index remain unclear. Methods: This nationwide retrospective cohort study included 323 029 adults with newly diagnosed type 2 diabetes and a normal body mass index (2 ) between January 1, 2010, and December 31, 2023, from the Korean National Health Insurance Service database. Abdominal obesity was defined using sex‐specific waist circumference thresholds (≥90 cm for men, ≥80 cm for women). MVPA was assessed through standardized self‐reported questionnaires administered during routine health screenings. The primary outcome was major adverse cardiovascular and cerebrovascular events, defined as a composite of all‐cause death, myocardial infarction, ischemic stroke, or hospitalization for heart failure. Results: Among the study population, 34 033 (10.5%) had abdominal obesity. During a median follow‐up of 6.0 years (interquartile range, 2.6–9.0 years), abdominal obesity was associated with a higher risk of major adverse cardiovascular and cerebrovascular events (adjusted hazard ratio [HR], 1.13 [95% CI, 1.09–1.17]). Among patients with abdominal obesity, regular MVPA after diagnosis (27.1%) was associated with a significantly lower risk of major adverse cardiovascular and cerebrovascular events (adjusted HR 0.74 [95% CI, 0.68–0.80]), all‐cause mortality (adjusted HR 0.72 [95% CI, 0.65–0.80]), ischemic stroke (adjusted HR 0.77 [95% CI, 0.66–0.89]), and hospitalization for heart failure (adjusted HR 0.75 [95% CI, 0.60–0.93]). The cardiovascular protective effects of MVPA were consistent regardless of statin or antidiabetic medication use. Conclusions: In patients with type 2 diabetes and a normal body mass index, abdominal obesity was independently associated with a higher risk of major adverse cardiovascular and cerebrovascular events. Regular engagement in MVPA showed consistent cardiovascular benefits in this population, irrespective of pharmacotherapy. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT07071545.
- 29 October 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
Clopidogrel Versus Aspirin Monotherapy According to Atherothrombotic Risk Profile
BACKGROUND: Clopidogrel monotherapy has shown superior efficacy compared with aspirin after completion of dual antiplatelet therapy following percutaneous coronary intervention (PCI). However, whether treatment effects differ according to overall atherothrombotic risk integrating clinical and angiographic factors remains unclear. METHODS: This post hoc analysis of the SMART-CHOICE 3 (Smart Angioplasty Research Team: Choice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3) randomized trial included patients who completed guideline-directed dual antiplatelet therapy after PCI. Atherothrombotic risk was defined using the a Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention and complex PCI. Patients with Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention ≥3 or complex PCI were classified as higher risk, and those with a Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention P =0.007). In higher-risk patients, clopidogrel reduced major adverse cardiac and cerebrovascular events compared with aspirin (4.6% versus 7.4%; hazard ratio, 0.67 [95% CI, 0.50–0.89]; P =0.006), with no difference in lower-risk patients (3.0% versus 3.2%; hazard ratio, 1.03; P =0.945; interaction P =0.242). Bleeding was similar between groups. CONCLUSIONS: After completion of dual antiplatelet therapy following PCI, clopidogrel monotherapy was associated with lower ischemic risk than aspirin in patients with higher atherothrombotic risk, without increased bleeding. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04418479.
- 29 October 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
Clopidogrel Versus Aspirin Monotherapy According to Atherothrombotic Risk Profile
BACKGROUND: Clopidogrel monotherapy has shown superior efficacy compared with aspirin after completion of dual antiplatelet therapy following percutaneous coronary intervention (PCI). However, whether treatment effects differ according to overall atherothrombotic risk integrating clinical and angiographic factors remains unclear. METHODS: This post hoc analysis of the SMART-CHOICE 3 (Smart Angioplasty Research Team: Choice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3) randomized trial included patients who completed guideline-directed dual antiplatelet therapy after PCI. Atherothrombotic risk was defined using the a Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention and complex PCI. Patients with Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention ≥3 or complex PCI were classified as higher risk, and those with a Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention P =0.007). In higher-risk patients, clopidogrel reduced major adverse cardiac and cerebrovascular events compared with aspirin (4.6% versus 7.4%; hazard ratio, 0.67 [95% CI, 0.50–0.89]; P =0.006), with no difference in lower-risk patients (3.0% versus 3.2%; hazard ratio, 1.03; P =0.945; interaction P =0.242). Bleeding was similar between groups. CONCLUSIONS: After completion of dual antiplatelet therapy following PCI, clopidogrel monotherapy was associated with lower ischemic risk than aspirin in patients with higher atherothrombotic risk, without increased bleeding. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04418479.
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19) , e050187
Restricted Loss of Life Expectancy in Patients With Acute Myocardial Infarction: A Nationwide KAMIR Registry Study
Background: The mortality risk of acute myocardial infarction declines rapidly after the initial period, yet the quantitative measures of residual risk in the follow‐up period remain limited. We aimed to assess restricted loss of life expectancy (LOLE) in patients with acute myocardial infarction. Methods: We included patients from KAMIR (Korea Acute Myocardial Infarction Registry), a nationwide acute myocardial infarction registry, between 2012 and 2020. The survival of 27 705 patients (mean age, 64 years; 76% men) was compared with an age‐, sex‐, and calendar year–matched reference cohort derived from Korean population life tables. Three‐year restricted LOLE was estimated using a Royston–Parmar flexible parametric survival model adjusted for clinical characteristics. Results: Overall, 3‐year restricted LOLE was 23 (95% CI, 22–25) days. In subgroup analyses, older age (≥75 years, 42 [95% CI, 37–47] days versus <50 years, 7 [95% CI, 3–10] days), female sex (44 [95% CI, 37–51] days versus male sex, 14 [95% CI, 11–17] days), and lower left ventricular ejection fraction (≤40%; 135 [95% CI, 128–142] days versus ≥50%, 0 [−2 to 1] days) were associated with higher 3‐year restricted LOLE. Across the study period, 3‐year restricted LOLE nearly halved from 36 (95% CI, 31–41) to 16 (95% CI, 9–23) days. Conclusions: Restricted LOLE provides intuitive, patient‐centered measures of residual risk after acute myocardial infarction. It also demonstrated a significant improvements in patient outcomes over the study period.
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19) , e050187
Restricted Loss of Life Expectancy in Patients With Acute Myocardial Infarction: A Nationwide KAMIR Registry Study
Background: The mortality risk of acute myocardial infarction declines rapidly after the initial period, yet the quantitative measures of residual risk in the follow‐up period remain limited. We aimed to assess restricted loss of life expectancy (LOLE) in patients with acute myocardial infarction. Methods: We included patients from KAMIR (Korea Acute Myocardial Infarction Registry), a nationwide acute myocardial infarction registry, between 2012 and 2020. The survival of 27 705 patients (mean age, 64 years; 76% men) was compared with an age‐, sex‐, and calendar year–matched reference cohort derived from Korean population life tables. Three‐year restricted LOLE was estimated using a Royston–Parmar flexible parametric survival model adjusted for clinical characteristics. Results: Overall, 3‐year restricted LOLE was 23 (95% CI, 22–25) days. In subgroup analyses, older age (≥75 years, 42 [95% CI, 37–47] days versus <50 years, 7 [95% CI, 3–10] days), female sex (44 [95% CI, 37–51] days versus male sex, 14 [95% CI, 11–17] days), and lower left ventricular ejection fraction (≤40%; 135 [95% CI, 128–142] days versus ≥50%, 0 [−2 to 1] days) were associated with higher 3‐year restricted LOLE. Across the study period, 3‐year restricted LOLE nearly halved from 36 (95% CI, 31–41) to 16 (95% CI, 9–23) days. Conclusions: Restricted LOLE provides intuitive, patient‐centered measures of residual risk after acute myocardial infarction. It also demonstrated a significant improvements in patient outcomes over the study period.
- 5 October 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
Derivation and Validation of Operational Definitions From Claims Data for Identifying Cardiogenic Shock
Objectives: To derive and validate a claims-based operational definition for cardiogenic shock (CS) using administrative data against clinically adjudicated reference standards. Design: Diagnostic accuracy study. Setting: Two independent clinical cohorts, a single-center cardiac ICU (CICU) registry and a multicenter CS registry (REtrospective and prospective observational Study to investigate Clinical oUtcomes and Efficacy of left ventricular assist device for Korean patients with cardiogenic shock [RESCUE]), and a nationwide administrative database from the Korean National Health Insurance Service. Patients: A total of 10,156 patients from the CICU registry and 1,247 patients from the RESCUE registry. For population-level application, 207,419 patients were identified from the national claims database. Interventions: None. Measurements and Main Results: A claims-based algorithm defined CS using the International Classification of Diseases , 10th Revision code R57.0 or cardiac disease codes combined with treatment-based criteria reflecting hemodynamic support, including mechanical circulatory support or vasoactive therapy. In the CICU cohort, the algorithm demonstrated a sensitivity of 0.89 and specificity of 0.90, with an overall accuracy of 0.90. In the RESCUE cohort, sensitivity was 0.95. When applied to the nationwide database, 207,419 patients with CS were identified. The cumulative mortality rates were 37.9% at 12 months, 49.9% at 5 years, and 61.7% at 10 years. Conclusions: A claims-based definition combining diagnostic codes with treatment-based criteria demonstrated high diagnostic performance for identifying CS. This approach enables reliable large-scale epidemiologic studies and long-term outcome assessments using administrative data and may facilitate system-level evaluation of critical care delivery in patients with CS.
- 5 October 2026
- Published by Wolters Kluwer Health in Critical Care Medicine
Derivation and Validation of Operational Definitions From Claims Data for Identifying Cardiogenic Shock
Objectives: To derive and validate a claims-based operational definition for cardiogenic shock (CS) using administrative data against clinically adjudicated reference standards. Design: Diagnostic accuracy study. Setting: Two independent clinical cohorts, a single-center cardiac ICU (CICU) registry and a multicenter CS registry (REtrospective and prospective observational Study to investigate Clinical oUtcomes and Efficacy of left ventricular assist device for Korean patients with cardiogenic shock [RESCUE]), and a nationwide administrative database from the Korean National Health Insurance Service. Patients: A total of 10,156 patients from the CICU registry and 1,247 patients from the RESCUE registry. For population-level application, 207,419 patients were identified from the national claims database. Interventions: None. Measurements and Main Results: A claims-based algorithm defined CS using the International Classification of Diseases , 10th Revision code R57.0 or cardiac disease codes combined with treatment-based criteria reflecting hemodynamic support, including mechanical circulatory support or vasoactive therapy. In the CICU cohort, the algorithm demonstrated a sensitivity of 0.89 and specificity of 0.90, with an overall accuracy of 0.90. In the RESCUE cohort, sensitivity was 0.95. When applied to the nationwide database, 207,419 patients with CS were identified. The cumulative mortality rates were 37.9% at 12 months, 49.9% at 5 years, and 61.7% at 10 years. Conclusions: A claims-based definition combining diagnostic codes with treatment-based criteria demonstrated high diagnostic performance for identifying CS. This approach enables reliable large-scale epidemiologic studies and long-term outcome assessments using administrative data and may facilitate system-level evaluation of critical care delivery in patients with CS.
- Open Access
- 2 October 2026
- Published by Elsevier in SSRN Electronic Journal
Smoking Cessation, E-Cigarette Use, Continued Smoking, and Cardiovascular Outcomes after Diagnosis of Type 2 Diabetes: A Nationwide Cohort Study
Background: Smoking cessation after a diagnosis of type 2 diabetes mellitus (T2DM) lowers cardiovascular risk, but sustained abstinence is difficult and e-cigarettes are promoted as an alternative. Whether switching to e-cigarettes confers comparable benefit is unknown.Methods: This nationwide cohort study used the Korean National Health Insurance Service database. Adults aged 40–74 years newly diagnosed with T2DM between Jan 1, 2018, and Dec 31, 2023, who smoked at the examination preceding diagnosis were included. Self-reported behaviour at the first examination after diagnosis (the index date) defined three groups: quitters, e-cigarette users, and continued combustible cigarette users. The primary outcome was myocardial infarction. Hazard ratios were estimated with Cox proportional hazards models weighted by stabilised inverse probability of treatment weights (IPTW). This study is registered with ClinicalTrials.gov, NCT07414355.Findings: Of 164,859 participants, 31,539 were quitters, 36,801 were e-cigarette users, and 96,519 continued smoking. Over a median 2·1 years (IQR:1·1–3·4), myocardial infarction occurred at 0·8, 1·4, and 1·7 events per 1000 person-years, respectively. Compared with quitters, risk was higher in e-cigarette users (IPTW-adjusted HR:1·78, 95%CI:1·21–2·62) and in continued smokers (HR:2·17, 95%CI:1·66–2·83); risk in e-cigarette users did not differ from that in continued smokers (HR:0·82, 95%CI:0·61–1·12). The pattern was similar for coronary revascularisation (HR:1·26, 95%CI:1·00–1·60 for e-cigarette users and HR:1·23, 95%CI:1·07–1·42 for continued smokers, respectively). Continued smokers also had higher risks of ischaemic stroke (HR:1·20, 95%CI:1·03–1·39) and all-cause death (HR:1·49, 95%CI:1·28–1·73), whereas estimates for e-cigarette users were 0·98 (95%CI:0·72–1·33) and 1·04 (95%CI:0·77–1·42). Dual users, who comprised 24,987 (67·9%) of e-cigarette users, had a higher myocardial infarction risk than complete switchers (HR:2·03, 95%CI:1·17–3·53).Interpretation: Among adults with newly diagnosed T2DM who smoked, cessation was associated with the lowest risk of coronary events, and switching to e-cigarettes did not reproduce this benefit. Risks of stroke and death in e-cigarette users did not differ from those in quitters, but follow-up was short. E-cigarettes should not be regarded as equivalent to cessation after a diagnosis of T2DM.
- 2 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSmoking Cessation, E-Cigarette Use, Continued Smoking, and Cardiovascular Outcomes after Diagnosis of Type 2 Diabetes: A Nationwide Cohort Study
Background: Smoking cessation after a diagnosis of type 2 diabetes mellitus (T2DM) lowers cardiovascular risk, but sustained abstinence is difficult and e-cigarettes are promoted as an alternative. Whether switching to e-cigarettes confers comparable benefit is unknown.Methods: This nationwide cohort study used the Korean National Health Insurance Service database. Adults aged 40–74 years newly diagnosed with T2DM between Jan 1, 2018, and Dec 31, 2023, who smoked at the examination preceding diagnosis were included. Self-reported behaviour at the first examination after diagnosis (the index date) defined three groups: quitters, e-cigarette users, and continued combustible cigarette users. The primary outcome was myocardial infarction. Hazard ratios were estimated with Cox proportional hazards models weighted by stabilised inverse probability of treatment weights (IPTW). This study is registered with ClinicalTrials.gov, NCT07414355.Findings: Of 164,859 participants, 31,539 were quitters, 36,801 were e-cigarette users, and 96,519 continued smoking. Over a median 2·1 years (IQR:1·1–3·4), myocardial infarction occurred at 0·8, 1·4, and 1·7 events per 1000 person-years, respectively. Compared with quitters, risk was higher in e-cigarette users (IPTW-adjusted HR:1·78, 95%CI:1·21–2·62) and in continued smokers (HR:2·17, 95%CI:1·66–2·83); risk in e-cigarette users did not differ from that in continued smokers (HR:0·82, 95%CI:0·61–1·12). The pattern was similar for coronary revascularisation (HR:1·26, 95%CI:1·00–1·60 for e-cigarette users and HR:1·23, 95%CI:1·07–1·42 for continued smokers, respectively). Continued smokers also had higher risks of ischaemic stroke (HR:1·20, 95%CI:1·03–1·39) and all-cause death (HR:1·49, 95%CI:1·28–1·73), whereas estimates for e-cigarette users were 0·98 (95%CI:0·72–1·33) and 1·04 (95%CI:0·77–1·42). Dual users, who comprised 24,987 (67·9%) of e-cigarette users, had a higher myocardial infarction risk than complete switchers (HR:2·03, 95%CI:1·17–3·53).Interpretation: Among adults with newly diagnosed T2DM who smoked, cessation was associated with the lowest risk of coronary events, and switching to e-cigarettes did not reproduce this benefit. Risks of stroke and death in e-cigarette users did not differ from those in quitters, but follow-up was short. E-cigarettes should not be regarded as equivalent to cessation after a diagnosis of T2DM.
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (17)
Artificial Intelligence‐Driven Angiographic Quantification of Fractional Flow Reserve: Proof‐of‐Concept Validation Study
Background: Angiography‐based fractional flow reserve (FFR) techniques offer wire‐free alternatives but often require manual segmentation and 3‐dimensional reconstruction. Although an artificial intelligence‐driven approach automates these steps, validation remains limited. This study investigated the diagnostic performance of an artificial intelligence‐driven angiography‐based FFR (medipixel FFR [MPFFR]), compared with quantitative flow ratio (QFR) in predicting functionally significant coronary artery stenosis defined by FFR ≤0.80. Methods: A total of 599 vessels from 452 patients who underwent clinically indicated FFR measurement were prospectively enrolled from 5 university hospitals in Korea. MPFFR used automated processes in frame selection, artificial intelligence contour detection, corresponding points matching, 3‐dimensional reconstruction, and analytical hemodynamic modeling. The primary end point was diagnostic accuracy for detecting FFR ≤0.80. Secondary end points were target vessel failure (composite of cardiac death, target‐vessel myocardial infarction, and target‐vessel revascularization) at 2 years. Results: Mean analysis time of MPFFR was 12.5±1.7 seconds and manual correction was needed in 32 vessels (5.3%). MPFFR showed similar diagnostic performance with QFR (correlation with FFR; MPFFR versus QFR: R=0.885 versus R=0.860, P for comparison=0.011; area under the curve to predict FFR ≤0.80; 0.949 versus 0.953, P for comparison=0.631). At a median follow‐up of 2 years (interquartile range, 1.6–2.6 years), patients with MPFFR ≤0.80 had higher risk of target vessel failure than those with MPFFR >0.80 (4.5% versus 0.8%; adjusted hazard ratio, 5.94 [95% CI, 1.27–27.91]; P =0.024). C‐index to predict target vessel failure was comparable between MPFFR and QFR (0.770 versus 0.753, P for comparison=0.469). Conclusions: In this multicenter registry, an artificial intelligence‐driven angiography‐based FFR demonstrated comparable diagnostic accuracy with QFR in identifying functionally significant stenosis, and similar prognostic ability with QFR in terms of target vessel failure at 2 years. Registration: Multicenter QFR Registry; Unique Identifier: NCT03791788.
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (17)
Open AccessArtificial Intelligence‐Driven Angiographic Quantification of Fractional Flow Reserve: Proof‐of‐Concept Validation Study
Background: Angiography‐based fractional flow reserve (FFR) techniques offer wire‐free alternatives but often require manual segmentation and 3‐dimensional reconstruction. Although an artificial intelligence‐driven approach automates these steps, validation remains limited. This study investigated the diagnostic performance of an artificial intelligence‐driven angiography‐based FFR (medipixel FFR [MPFFR]), compared with quantitative flow ratio (QFR) in predicting functionally significant coronary artery stenosis defined by FFR ≤0.80. Methods: A total of 599 vessels from 452 patients who underwent clinically indicated FFR measurement were prospectively enrolled from 5 university hospitals in Korea. MPFFR used automated processes in frame selection, artificial intelligence contour detection, corresponding points matching, 3‐dimensional reconstruction, and analytical hemodynamic modeling. The primary end point was diagnostic accuracy for detecting FFR ≤0.80. Secondary end points were target vessel failure (composite of cardiac death, target‐vessel myocardial infarction, and target‐vessel revascularization) at 2 years. Results: Mean analysis time of MPFFR was 12.5±1.7 seconds and manual correction was needed in 32 vessels (5.3%). MPFFR showed similar diagnostic performance with QFR (correlation with FFR; MPFFR versus QFR: R=0.885 versus R=0.860, P for comparison=0.011; area under the curve to predict FFR ≤0.80; 0.949 versus 0.953, P for comparison=0.631). At a median follow‐up of 2 years (interquartile range, 1.6–2.6 years), patients with MPFFR ≤0.80 had higher risk of target vessel failure than those with MPFFR >0.80 (4.5% versus 0.8%; adjusted hazard ratio, 5.94 [95% CI, 1.27–27.91]; P =0.024). C‐index to predict target vessel failure was comparable between MPFFR and QFR (0.770 versus 0.753, P for comparison=0.469). Conclusions: In this multicenter registry, an artificial intelligence‐driven angiography‐based FFR demonstrated comparable diagnostic accuracy with QFR in identifying functionally significant stenosis, and similar prognostic ability with QFR in terms of target vessel failure at 2 years. Registration: Multicenter QFR Registry; Unique Identifier: NCT03791788.
- 28 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Microvascular resistance reserve and cardiovascular outcomes: the FLOW-CMD registry
Background and Aims: Microvascular resistance reserve (MRR) is a novel index for assessing coronary microvascular function that is independent of epicardial coronary artery stenosis and subtended myocardial mass. However, limited data are available regarding the clinical relevance of coronary microvascular dysfunction, defined by MRR, in patients undergoing clinically indicated invasive coronary angiography. This study sought to evaluate the incidence and prognostic impact of coronary microvascular dysfunction defined by MRR in routine practice. Methods: In the prospective, multicentre FLOW-CMD Registry, 1003 consecutive patients with suspected ischaemic heart disease who underwent clinically indicated invasive coronary angiography with comprehensive coronary physiologic assessment were prospectively enrolled. Coronary microvascular dysfunction was defined as MRR ≤2.5 in any evaluated vessel. The primary endpoint was a composite of all-cause death, myocardial infarction, clinically-driven repeat revascularization, or hospitalization for heart failure. Results: Coronary microvascular dysfunction was identified in 334 of 1003 patients (33.3%). MRR as a continuous variable was associated with the risk of the primary endpoint (hazard ratio [HR] per 1-unit decrease, 1.16; 95% confidence interval [CI] 1.03–1.32; P = .026). At a median follow-up of 1.9 years, the primary endpoint occurred in 47 of 334 patients (18.2%) with coronary microvascular dysfunction and 49 of 669 patients (8.6%) with preserved microvascular function (HR 1.94; 95% CI 1.30–2.90; P = .001). On multivariable analysis, coronary microvascular dysfunction defined by MRR ≤2.5 was independently associated with the primary endpoint (adjusted HR 1.78; 95% CI 1.06–2.99; P = .030). Conclusions: In patients with suspected ischaemic heart disease undergoing invasive coronary angiography, coronary microvascular dysfunction defined by MRR ≤2.5 was observed among one-third of patients, and was associated with an increased risk of a composite of all-cause death, myocardial infarction, clinically-driven repeat revascularization, or hospitalization for heart failure (Multicenter FLOW-CMD Registry ClinicalTrials.gov number, NCT05369182).
- 28 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Microvascular resistance reserve and cardiovascular outcomes: the FLOW-CMD registry
Background and Aims: Microvascular resistance reserve (MRR) is a novel index for assessing coronary microvascular function that is independent of epicardial coronary artery stenosis and subtended myocardial mass. However, limited data are available regarding the clinical relevance of coronary microvascular dysfunction, defined by MRR, in patients undergoing clinically indicated invasive coronary angiography. This study sought to evaluate the incidence and prognostic impact of coronary microvascular dysfunction defined by MRR in routine practice. Methods: In the prospective, multicentre FLOW-CMD Registry, 1003 consecutive patients with suspected ischaemic heart disease who underwent clinically indicated invasive coronary angiography with comprehensive coronary physiologic assessment were prospectively enrolled. Coronary microvascular dysfunction was defined as MRR ≤2.5 in any evaluated vessel. The primary endpoint was a composite of all-cause death, myocardial infarction, clinically-driven repeat revascularization, or hospitalization for heart failure. Results: Coronary microvascular dysfunction was identified in 334 of 1003 patients (33.3%). MRR as a continuous variable was associated with the risk of the primary endpoint (hazard ratio [HR] per 1-unit decrease, 1.16; 95% confidence interval [CI] 1.03–1.32; P = .026). At a median follow-up of 1.9 years, the primary endpoint occurred in 47 of 334 patients (18.2%) with coronary microvascular dysfunction and 49 of 669 patients (8.6%) with preserved microvascular function (HR 1.94; 95% CI 1.30–2.90; P = .001). On multivariable analysis, coronary microvascular dysfunction defined by MRR ≤2.5 was independently associated with the primary endpoint (adjusted HR 1.78; 95% CI 1.06–2.99; P = .030). Conclusions: In patients with suspected ischaemic heart disease undergoing invasive coronary angiography, coronary microvascular dysfunction defined by MRR ≤2.5 was observed among one-third of patients, and was associated with an increased risk of a composite of all-cause death, myocardial infarction, clinically-driven repeat revascularization, or hospitalization for heart failure (Multicenter FLOW-CMD Registry ClinicalTrials.gov number, NCT05369182).
- 17 August 2026
- Published by Wolters Kluwer Health in ASAIO Journal
Association of Shock-to-Balloon Time With Outcomes in Acute Myocardial Infarction With Cardiogenic Shock Requiring VA-ECMO
The optimal timing of percutaneous coronary intervention (PCI) in patients with acute myocardial infarction complicated by cardiogenic shock (AMI-CS) who are supported with venoarterial extracorporeal membrane oxygenation (VA-ECMO) remains uncertain. We aimed to evaluate the prognostic impact of shock-to-balloon time (STB) in AMI-CS patients supported with VA-ECMO before revascularization. This study included patient-pooled data from CS-dedicated registries, including the SMART-RESCUE and the SMC-ECMO. A total of 256 patients were included. Patients were stratified according to STB (vs . 44.6%; adjusted hazard ratio [HR]: 1.59, 95% confidence interval [CI]: 1.03–2.45, p = 0.037). This association was significant in the ST-segment elevation myocardial infarction (STEMI) subgroup (adjusted HR: 2.22, 95% CI: 1.26–3.93), and in patients with earlier (p -for-interaction = 0.164). In AMI-CS patients who underwent VA-ECMO, a prolonged STB was associated with higher all-cause mortality, with a consistent but exploratory trend in NSTEMI. These findings support STB as a prognostic marker and warrant prospective evaluation of coordinated ECMO-revascularization pathways.
- 17 August 2026
- Published by Wolters Kluwer Health in ASAIO Journal
Association of Shock-to-Balloon Time With Outcomes in Acute Myocardial Infarction With Cardiogenic Shock Requiring VA-ECMO
The optimal timing of percutaneous coronary intervention (PCI) in patients with acute myocardial infarction complicated by cardiogenic shock (AMI-CS) who are supported with venoarterial extracorporeal membrane oxygenation (VA-ECMO) remains uncertain. We aimed to evaluate the prognostic impact of shock-to-balloon time (STB) in AMI-CS patients supported with VA-ECMO before revascularization. This study included patient-pooled data from CS-dedicated registries, including the SMART-RESCUE and the SMC-ECMO. A total of 256 patients were included. Patients were stratified according to STB (vs . 44.6%; adjusted hazard ratio [HR]: 1.59, 95% confidence interval [CI]: 1.03–2.45, p = 0.037). This association was significant in the ST-segment elevation myocardial infarction (STEMI) subgroup (adjusted HR: 2.22, 95% CI: 1.26–3.93), and in patients with earlier (p -for-interaction = 0.164). In AMI-CS patients who underwent VA-ECMO, a prolonged STB was associated with higher all-cause mortality, with a consistent but exploratory trend in NSTEMI. These findings support STB as a prognostic marker and warrant prospective evaluation of coordinated ECMO-revascularization pathways.